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Jacob Fog Bentzon, MD, PhD
Background-—Treatment of prostate cancer often involves androgen deprivation therapy (ADT) by gonadotropin-releasing hormone
(GnRH) receptor agonists, GnRH receptor antagonists, or orchiectomy. ADT may increase the rate of cardiovascular disease events,
but recent clinical studies suggested that not all means of ADT carry the same risk, raising the possibility of non–testosterone-
mediated effects of different forms of ADT on atherosclerosis. Here we compared effects of ADT on atherosclerosis in intact and
orchiectomized Apoe-deficient mice.
Methods and Results-—Chow-fed Apoe-deficient mice were allocated to orchiectomy and/or monthly injections with the GnRH
receptor agonist leuprolide or the GnRH receptor antagonist degarelix. Atherosclerosis was quantified at 26 weeks of age in the
aortic arch by en face examination and in the aortic root by histology. In intact Apoe-deficient mice, all types of ADT reduced
testosterone production to castration levels. Although hypercholesterolemia was accentuated in leuprolide-treated mice, the
amount and composition of atherosclerosis was not different between the different types of ADT. In orchiectomized Apoe-deficient
mice, leuprolide, but not degarelix, augmented hypercholesterolemia, changed body, thymus, and spleen weights, and increased
atherosclerosis in the aortic root. No direct effects of the drugs were detectable on cytokine secretion from murine bone marrow–
derived macrophages or on splenocyte proliferation.
Conclusions-—No differences in the development of atherosclerosis were detected among groups of intact Apoe-deficient mice
treated with different types of ADT. A pro-atherogenic, possibly cholesterol-mediated, effect of leuprolide was seen in
orchiectomized mice that might be relevant for understanding the potential cardiovascular risk associated with GnRH agonist-
based ADT. ( J Am Heart Assoc. 2016;5:e002800 doi: 10.1161/JAHA.115.002800)
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P rostate cancer (PCa) is one of the most commonmalignancies in aging men across the world.1 An
important part of the treatment for many PCa patients is
androgen deprivation therapy (ADT), which lowers testos-
terone either by blockade or agonist-induced desensitization
of pituitary gonadotropin-releasing hormone (GnRH) receptors
or the surgical removal of the testes.2 ADT is the first-line
treatment for metastatic PCa and an adjuvant therapy to
radiotherapy for locally advanced PCa. Unfortunately, apart
from improving survival and quality of life, ADT treatment has
been associated with an excess risk of cardiovascular disease
(CVD), including myocardial infarction.2–7
Traditionally the increased risk of CVD in patients treated
with ADT has been attributed to alterations in metabolic
parameters that are known or assumed to influence the
development of atherosclerosis, such as an increase in
subcutaneous fat, total cholesterol, triglycerides, and
decreased insulin sensitivity.3 These changes appear to result
from testosterone deficiency, since testosterone supplemen-
tation in hypogonadal men has opposite effects.8 Recent
studies, however, have suggested that the number of CVD
events in PCa patients differs between different types of ADT,
indicating that other mechanisms than the mere lack of
testosterone is involved. In observational studies and a post
hoc analysis of randomized controlled trials, a higher rate of
CVD events was found in patients treated with GnRH receptor
agonists compared with bilateral orchiectomy or GnRH
antagonists.4,5,9 These studies are hypothesis-generating
and the findings await confirmation in randomized trials with
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CVD as a prespecified end point, but the idea of a divergent
effect of orchiectomy, GnRH agonists and antagonists on
atherosclerosis-related disease is supported by experimental
studies. Atherosclerosis is a lipoprotein-driven immuno-
inflammatory disease,10 and the presence and functional role
of GnRH receptors have been documented in both a murine
macrophage cell line and in rat and human lymphocytes
in vitro.11–13 Furthermore, stimulation of the GnRH receptor
with agonists have been shown to exacerbate lupus in
castrated mice,14 whereas treatment with an antagonist
delayed the onset of autoimmune diabetes,15 both indicating
potential modulations of the immune response. Two studies
on initial foam cell accumulation in hypercholesterolemic mice
have recently been reported, indicating an anti-atherogenic
effect of GnRH receptor antagonists compared to placebo or
GnRH agonists, respectively,16,17 but effects on more
advanced atherosclerotic lesions have not been addressed.
In the present study, we addressed the hypothesis that
different types of ADT may exert variable effects on the




Homozygous Apoe-deficient mice (B6.129P2-Apoetm1Unc)
(n=124), backcrossed more than 10 generations into the
C57BL/6 background, and wild-type C57BL/6NTac mice
were obtained from Taconic (Ry, Denmark). The mice had free
access to tap water and were fed chow diet. All procedures
were approved by the Danish Animal Experiments Inspec-
torate and were in accordance with institutional guidelines
and the Directive 2010/63/EU of the European Parliament.
Bilateral Orchiectomy
Bilateral orchiectomy was performed in some Apoe-deficient
mice by trained personal at Taconic (Ry, Denmark) when they
were 5 weeks old. The mice were anesthetized by an intraperi-
toneal injection of 0.1 mL of a mixture containing xylazine
(Rompun) (20 mg/mL, 0.39 mL), ketamine (Ketaminol)
(100 mg/mL, 0.39 mL), acepromazine (Calmivet) (5 mg/mL,
0.24 mL), and isotonic NaCl (1.98 mL). Analgesia was secured
using carprofen (50 mg/mL, 0.1 mL) injected subcutaneously.
Administration of ADT
Groups of intact and orchiectomized Apoe-deficient mice were
injected subcutaneously with saline, 0.5 mg leuprolide (Eli-
gard), or 0.5 mg degarelix (Firmagon) every 4 weeks com-
mencing at 8 weeks of age (Figure 1). Both Eligard and
Firmagon were reconstituted as indicated in the package
insert for human use and the volume of suspension appro-
priate to deliver a dose of 0.5 mg was injected subcuta-
neously. Three mice died during the course of the study: one
saline-injected orchiectomized mouse, one leuprolide-injected
mouse, and one degarelix-injected mouse.
Atherosclerosis Quantification
At 26 weeks of age, the Apoe-deficient mice were anesthetized
with an intraperitoneal injection of pentobarbital (250 mg/kg)
and lidocaine (20 mg/kg) and euthanized by withdrawal of
blood from the right ventricle. The mice were flushed with
Cardioplex solution, perfusion-fixed with 4% formaldehyde via
the left ventricle, immersed in 4% formaldehyde for 6 hours,
and stored in phosphate-buffered saline at 5°C. For quantifi-
cation of atherosclerosis in the aortic root, the top half of the
heart was embedded in paraffin. Sections taken at 80-lm
intervals from the commissures of the aortic leaflets and
upward (3 levels in total) were stained with orcein and sirius
red. Atherosclerotic plaque size was quantified in orcein-
stained sections by computer-assisted morphometry (ImageJ,
NIH). Necrotic core area was quantified in sirius red–stained
sections. Necrosis was defined as the absence of collagen and
viable cells, the latter judged from the orcein-stained sections.
Aortic arch lesion coverage was measured en face using a
standard method. Briefly, the aorta down to the first
intercostal artery was cut open, stained with Oil Red O for
10 minutes at 37°C, and mounted on a microscope slide with
AquaTex. Slides were scanned and analyzed using ImageJ.
Blood Analysis
Nonfasting total plasma cholesterol was measured using a
commercially available kit (Cholesterol CHOD-PAP, Roche/
Figure 1. Effect of different doses of leuprolide and degarelix in
male mice. The decline was slower with leuprolide, but both drugs
led to measured testosterone levels indistinguishable from
orchiectomized mice at both dosing levels tested. Number of
mice in each group: Control (n=4), orchiectomy (n=4), degarelix
2 mg (n=3), degarelix 0.5 mg (n=4), leuprolide 2 mg (n=4),
leuprolide 0.5 mg (n=4).
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Hitachi). Distribution of cholesterol across size-fractionated
lipoproteins was measured in pooled samples from each
group by fast protein liquid chromatography in the Gaubius
Laboratory, (TNO Biosciences, the Netherlands). Testosterone
was measured in plasma samples using a commercially
available mouse competitive ELISA kit with a reported
analytical sensitivity limit of 0.1 ng/mL (DRG Diagnostics).
Cell Culture Assays
Male C57BL/6NTac mice (9–12 weeks old) were euthanized
by cervical dislocation. Bone marrow cells were isolated from
femurs and tibias and cultured in RPMI medium supplemented
with 10% fetal bovine serum, 1% penicillin/streptomycin, and
10% L-cell conditioned medium for 7 days to generate bone
marrow–derived macrophages (BMM) as previously
described.18 BMMs were seeded at 1.59105 cells/well in
48-well plates and after 24 hours polarized towards an M1
phenotype with lipopolysaccharide (LPS, c-irradiated, L4391,
Sigma-Aldrich) at different concentrations: 1 ng/mL, 10 ng/
mL, and 100 ng/mL. Leuprolide acetate (H4060, Bachem)
and degarelix (Ferring Pharmaceuticals) were co-incubated
with the BMMs for 24 hours at a concentration of 106 mol/
L. Cytokine secretion into the cell culture medium was
subsequently analyzed using IL-6, tumor necrosis factor-a,
and interferon-c ELISAs (Ready-SET-Go Mouse kits, eBio-
science).
Splenocytes were isolated and seeded at 29105 cells/well
in 96-well plates as previously described.19 Cells were
activated with soluble anti-mouse CD3e antibody (BioLegend,
clone: 145-2C11) at different concentrations (0.3, 1.0, and
3.0 lg/mL) for 48 hours. Assessment of cell proliferation
was made using the Quick Cell Proliferation Assay Kit
(Abcam).
GnRH Receptor Expression in Tissue and Cultured
Cells
RNA was purified using TRIzol Reagent (Ambient #15596018)
from thymus, spleen, pituitary gland, cultured BMMs, and
cultured splenocytes obtained from male C57BL/6NTac mice
(9–12 weeks of age). BMMs and splenocytes were either
na€ıve or activated for 24 hours with 100 ng/mL LPS or for
48 hours with 3.0 lg soluble anti-mouse CD3e, respectively.
Conversion to cDNA was performed with iScript cDNA
synthesis kit (BioRad #170-8891) on 1 lg and 700 ng total
RNA from tissue samples and cultured cells, respectively. For
Gnrhr reverse transcription polymerase chain reaction (RT-
PCR), 1 lL of pituitary cDNA, and 7.5 lL of spleen or thymus
cDNA were used as templates using the following PCR
program: 94°C, 3 minutes for 91 cycle, 94°C for 20 s, 56°C
for 30 s, and 72°C for 1 minute 935 cycles, and 72°C for
7 minutes 91 cycle. b2-microglobulin was used as the
reference gene. For the b2-microglobulin RT-PCR, 0.5 lL
cDNA was used as template for all tissue and cell samples
using the following PCR program: 94°C, 3 minutes for 91
cycle, 94°C for 20 s, 60°C for 30 s, and 72°C for 25 s 935
cycles, and 72°C for 7 minutes 91 cycle. The primers 50-
TTCCACAGTGGTGGCATCAG-30 and 50-GTCCAGCAGACGA-
CAAAGGA-30 were used for amplification of the GnRH
receptor, whereas b2-microglobulin was detected using the
primers 50-CTGCTACGTAACACAGTTCCACCC-30 and 50-CAT-
GATGCTTGATCACATGTCTCG-30.
Statistics
All statistical analyses were performed using the Prism
statistical software (GraphPad, San Diego, CA). Data were
tested for normality using D’Agostino & Pearson omnibus
normality test, and normally distributed data were analyzed by
1-way ANOVA followed by Newman–Keuls post-test. Longitu-
dinal data such as weight and plasma cholesterol were
analyzed by 2-way ANOVA with repeated measures followed
by Bonferroni post-test. Necrotic core size data were log-
transformed before ANOVA was performed. Non-normally
distributed data were analyzed by the Kruskal–Wallis test with
Dunn’s multiple comparison test. Data are shown as mean 
SEM. In all cases P<0.05 was considered to be significant and
the following symbols were used to indicate the size of
P-values: *P<0.05, **P<0.01, ***P<0.001.
Results
Effective Treatment Dose
First we conducted a study to determine the lowest effective
dose of the GnRH agonist leuprolide and the antagonist
degarelix that reduced plasma testosterone to castration
levels in C57BL/6NTac mice (Figure 1). Leuprolide or
degarelix was injected subcutaneously at a dose of 2 or
0.5 mg per mouse each month in line with dosing regimens
reported by others.20 Both high and low doses reduced
plasma testosterone to the level of orchiectomized mice and
we chose the lower dose (0.5 mg) for the study. Attempts
were made to inject leuprolide at an even lower dose
(0.2 mg), but at this dosing level we found little effect on
plasma testosterone, which may partly be caused by difficul-
ties in administering the small volume of the viscous depot
formulation (data not shown).
ADT in Apoe-Deficient Mice
To analyze the effects of different forms of ADT, we allocated
Apoe-deficient mice into 6 groups as outlined in Figure 2. This
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design allowed for 2 prespecified statistical comparisons.
First, we planned to compare groups of mice subjected to
either orchiectomy or monthly injections of leuprolide,
degarelix, or saline to address our main hypothesis. Second,
we wanted to assess for potential non–testosterone-mediated
effects of both drugs by comparing orchiectomized-only mice
with groups of orchiectomized mice that also received
degarelix or leuprolide. Orchiectomy was performed when
the mice were 5 weeks old. Administration of drugs was
started at 8 weeks of age.
General Effects of Different Forms of ADT
Testosterone was measured 1, 2, and 4 months after
initiation of ADT. As expected, plasma testosterone concen-
tration decreased more slowly in the leuprolide compared to
the degarelix group (Figure 3A), but the differences between
ADT groups were not statistically significant. The decrease in
testosterone levels within each group was accompanied by
retarded weight gain during the 18 weeks of treatment
(Figure 3B). Following castration, total cholesterol increased
significantly in all groups (Figure 3C). The mice treated with
orchiectomy or degarelix reached a plateau after 2 months
and plasma concentrations stayed constant during the
remainder of the study. In leuprolide-treated mice, total
cholesterol increased further through the latter half of the
study and ended up significantly higher than that of the other
castrated groups. Size-exclusion chromatography of pooled
plasma lipoproteins from each group showed that the main
change in total cholesterol was due to changes in the very
low-density lipoprotein–sized fraction (Figure 3D).
To evaluate the possibility for a direct effect of GnRH
agonists acting through immune cell GnRH receptors, we
tested for the presence of GnRH receptor mRNA by RT-PCR in
thymus and spleen, but only found it faintly detectable in
thymus (Figure 3E). Significant increases in thymus weight
were seen with orchiectomy or degarelix, but not with
leuprolide (Figure 3F). Conversely, spleen weights were
unaffected in orchiectomized or degarelix-treated mice, but
reduced in leuprolide-treated mice (Figure 3G).
To assess for potential non–testosterone-mediated effects
of ADT, we performed similar analyses in orchiectomized mice
treated with leuprolide and degarelix (Figure 4). Degarelix
induced no significant changes in the measured parameters in
orchiectomized mice, but similar to the results in intact mice,
leuprolide was followed by increased weight gain, higher
cholesterol levels, and lower thymus and spleen weights.
Impact of Different Forms of ADT on
Atherosclerosis
To assess the effect of various forms of ADT on the
development of atherosclerosis, we quantified the amount
of disease in the aortic arch and aortic root by en face
measurements and histology, respectively. Orchiectomized
mice and mice receiving leuprolide or degarelix had signifi-
cantly increased atherosclerosis by both measures compared
to control mice (Figure 5A and 5B). In contrast to previous
studies reporting effects of castration on initial necrotic core
formation in hyperlipidemic mice,17,21 we did not find
significant increases in absolute or relative cross-sectional
area of the necrotic core in ADT compared to saline-treated
control mice (Figure 5C and 5D).
In orchiectomized mice, the addition of leuprolide, but not
degarelix, led to a further increase in atherosclerosis devel-
opment, which was, however, restricted to the aortic root
(Figure 6A and 6B). The increase may, at least in part, be a
reflection of the higher total cholesterol burden in this group.
Notably, however, we were not able to detect any significant
correlations between total cholesterol levels and aortic root or
arch atherosclerosis within any of the groups. Necrotic core
formation was not significantly affected by leuprolide or
degarelix in orchiectomized mice (Figure 6C and 6D).
Cell Studies
Previous experiments with LPS-treated RAW264.7 macro-
phages12 and anti-CD3 treated rat, mainly female, T lympho-
cytes13,22 have reported effects of GnRH receptor stimulation
on cellular activation and proliferation. These findings could
be relevant for atherosclerosis. LPS activates macrophages by
binding to Toll-like receptor 4, which also binds modified LDL
and has been implicated in murine atherosclerosis.23 Fur-
thermore, T lymphocytes recognizing atherosclerosis-related
auto-antigens modulate the progression of murine atheroscle-
rosis.24 We therefore re-investigated the impact of GnRH
receptor agonists and antagonists on macrophage and
lymphocyte activation using primary cells obtained from male
mice. First, we cultured BMM from male C57BL/6NTac mice





Orx + Degarelix, n=21 





8w 12w 16w 20w 24w 26w 
Figure 2. Outline of the study. The ages of the mice at the
designated time points (weeks) are indicated at the bottom.
Degarelix and leuprolide were injected subcutaneously at a dose
of 0.5 mg every 4 weeks. Control mice were injected with saline.
Orx, orchiectomy; n, number of mice in each group.
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LPS under concurrent stimulation or inhibition of the GnRH
receptor with leuprolide and degarelix, respectively. Although
the GnRH receptor was detectable in murine LPS-stimulated
BMM (Figure 7A), no differences were found in the secretion
of pro-inflammatory cytokines IL-6, monocyte chemoattrac-
tant protein-1, and tumor necrosis factor-a (Figure 7B through
7D). Furthermore, we found no differences of leuprolide or
degarelix on the proliferation of anti-CD3 stimulated spleno-
cytes (Figure 7E), and also were not able to detect GnRH
receptor mRNA in such cells (Figure 7A).
Discussion
In the present study, we tested the hypothesis that different
types of ADT exert differential effects on the development of
atherosclerosis in Apoe-deficient mice. This idea was sug-
gested by epidemiological studies and a recent meta-analysis
of clinical trials conducted in ADT-treated men with preexist-
ing CVD. We found that all forms of ADT reduced testosterone
production to levels of orchiectomized mice, increased
plasma total cholesterol, and accelerated atherosclerosis.
BA
DC
Figure 3. Effects of different forms of ADT in Apoe-deficient mice. A, Plasma concentration of testosterone in mice
after 1, 2, and 4 months of treatment. A random subset of mice from each group was analyzed with (n=10, 8, 12), (n=9,
9, 12), (n=9, 8, 11), and (n=7, 8, 12) measurements performed in the control, leuprolide, degarelix, and orchiectomized
(Orx) group at the 1-, 2-, and 4-month time points, respectively. B, Body weights in the different groups. A significant
difference in weight was found between control and ADT groups, and leuprolide-treated mice had higher final body
weight than mice of the other ADT groups. Number of animals in each group as indicated in Figure 2. C, Plasma total
cholesterol concentration at 2 and 4 months of treatment. After 2 months of treatment, total cholesterol levels were
significantly higher in ADT groups than in controls. Levels in leuprolide-treated mice increased further and were
significantly higher than other ADT groups at 4 months of treatment. For controls (n=20, 20), leuprolide (n=19, 19),
degarelix (n=18, 18), and orx (n=21, 21) measurements performed at 2 and 4 months, respectively. D, Distribution of
cholesterol across size-fractionated lipoprotein classes measured in pooled plasma from each group obtained 4 months
after treatment initiation. E, Detection of GnRH receptor mRNA in tissue samples from pituitary gland (Pit) and thymus.
No GnRH receptor mRNA was detected in spleen tissue from male mice. Pit-RT, Control reaction with omission of reverse
transcriptase. Expected band sizes were 237 bp (GnRH receptor) and 240 bp (b2-microglobulin). F, Thymus weights. G,
Spleen weights. P-values were calculated with Bonferroni post-test after 2-way ANOVA with repeated measures (B and
C), with Dunn’s multiple comparison test after significant Kruskal–Wallis test (F) and Neuman–Keuls post-test after
significant ANOVA (G). *P<0.05, **P<0.01, ***P<0.001. ADT, androgen deprivation therapy; GnRH, gonadotropin-
releasing hormone; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein.
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When applied in intact Apoe-deficient mice, the GnRH agonist
leuprolide aggravated hypercholesterolemia, but no significant
differential effects of the type of ADT on the amount or
composition of atherosclerosis were detected. In orchiec-
tomized Apoe-deficient mice, however, addition of leuprolide
increased both hypercholesterolemia and atherosclerosis in
the aortic root.
Effects of ADT on CVD
Among men with early stage PCa, atherosclerotic CVD rather
than the cancer itself is the leading cause of death.25
Epidemiological studies have implicated that ADT may be
partly responsible for the increased number of CVD events,
which is observed shortly after treatment initiation and most
notably in patients with preexisting atherosclerotic CVD.4,9
These observations are strongest for GnRH agonists, the most
common form of ADT, whereas data on orchiectomy are less
consistent and little information still exists pertaining to the
newer GnRH antagonists.9,26 In 2010, the combined obser-
vations led the U.S. Food and Drug Administration to put a
warning label on GnRH agonists regarding the suspected
increased risk of CVD (http://www.fda.gov/drugs/drug
safety/ucm229986.htm).
The mechanisms linking ADT to atherosclerotic CVD,
however, remain poorly understood. Traditionally the effects
have been ascribed to testosterone deficiency and its
consequences for metabolism and lipid profile, which include
increased low-density lipoprotein (LDL) and high-density
lipoprotein cholesterol, as well as changes in triglycerides,
fat distribution, and insulin sensitivity resembling those in
patients with the metabolic syndrome.3 However, even though
LDL particles fuel the atherosclerotic disease process and it is
well known that changes in LDL levels upon statin treatment
can exert relatively rapid effects on CVD end points,27 the
ADT-associated LDL increase is modest (<10%),3 and it is
doubtful whether the combined metabolic changes associated
with testosterone deficiency can provide a comprehensive
explanation for the acutely increased CVD risk associated
with ADT initiation. Interestingly, recent observational studies
and a meta-analysis of randomized controlled trials suggested
that non–testosterone-mediated effects of GnRH agonists
may be important for the increased risk of atherosclerotic
CVD.4,5 Bosco et al, using registry data, found that GnRH
agonist-based ADT was associated with a higher risk of CVD
than surgical orchiectomy.5 Furthermore, Albertsen et al, in a
meta-analysis of trials comparing the GnRH agonists leupro-
lide and goserelin to the GnRH antagonist degarelix, found
that agonist treatment was associated with a higher cardio-
vascular event rate in the subgroup of men with preexisting
CVD.4
Though these data might suggest a causal relationship,
they do not prove one. Observational studies are limited by
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and some of the characteristics of PCa patients used to guide
those decisions (eg, comorbidity, age, etc) could well
influence the rate of CVD events. Furthermore, being a
post-hoc and subgroup analysis based on pooled data, the
finding by Albertsen et al4 needs confirmation in randomized
trials with prespecified CVD end points.
Effects on ADT on Experimental Atherosclerosis
The Apoe-deficient mouse model, like other murine models, is
not a model of vulnerable plaque,28 but key mechanisms that
increase plaque vulnerability and thus clinical CVD in humans,
such as lipoprotein-driven inflammation and necrotic core
formation, can be studied.29 This supports the relevance of
this experimental model to probe for the potential non–
testosterone-mediated effects of GnRH agonists suggested by
clinical data.
We found that different forms of ADT all accelerated
atherogenesis in intact Apoe-deficient mice, but found no
detectable differences among ADT-treated groups. This
indicates that direct drug effects and other differences
between the modes of castration are not important for the
development of atherosclerosis in mice. In particular, it is in
contrast with a previous conclusion that circulating gonado-
tropins (ie, follicle-stimulating hormone and luteinizing hor-
mone levels), which are high with orchiectomy but low with
GnRH antagonists, influence atherogenesis in mice.16 On the
other hand, a non–testosterone-mediated, pro-atherogenic
effect of the GnRH agonist leuprolide in orchiectomized mice
was detected, and it was accompanied by several other
effects on total cholesterol, body weight, thymus, and spleen
weights that were exclusive to this type of ADT.
Although these non–testosterone-mediated effects of
leuprolide are notable, the data clearly raise several ques-
tions. Why did leuprolide only appear to be pro-atherogenic in
orchiectomized mice? Leuprolide led to a slower decline in
testosterone compared to orchiectomy or antagonist treat-
ment and unlike common practice in humans, we did not
compensate for this with supplemental anti-androgen




Figure 4. Effects of leuprolide and degarelix in orchiectomized Apoe-deficient mice. A, Body weights in orchiectomized (Orx) groups. Final
mean weight of leuprolide-treated mice was significantly higher than that of the other groups. Number of animals in each group as indicated in
Figure 2. B, Plasma total cholesterol measured after 2 and 4 months of treatment. At both time points, mean total cholesterol levels in the
leuprolide-treated group were higher than in the other groups. Number of measurements were (n=21, 21), (n=20, 21), and (n=20, 21) in the orx,
orx+leuprolide, and orx+degarelix groups at the 2- and 4-month time points, respectively. C, Distribution of cholesterol across size-fractionated
lipoprotein classes measured in pooled plasma from each group obtained 4 months after treatment initiation. D, Thymus weights. E, Spleen
weights. P-values were calculated with Bonferroni post-test after a 2-way ANOVA with repeated measures (A and B) or Dunn’s multiple
comparison test after significant Kruskal–Wallis test (D and E). *P<0.05, ***P<0.001.
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testosterone,30 the higher plasma testosterone level encoun-
tered during the study period may have masked a pro-
atherogenic effect of leuprolide in intact mice, but could not
interfere when the comparison was done in orchiectomized
mice. Importantly, unlike humans, mice do not produce
androgen in the adrenal glands, which might otherwise
confound the results.31 Why was the effect only noticeable
in the aortic root? It could be a Type 2 error in quantifying
atherosclerosis in the aortic arch, or be caused by the later
stage of lesion development in the aortic root, which would be
consistent with observational studies only showing an effect
in patients with known CVD.4,9 However, it also cannot be
excluded that the leuprolide-effect on atherosclerosis in the
aortic root was a chance finding altogether.
Increases in total cholesterol were found in both intact and
orchiectomized leuprolide-treated mice, and size-exclusion
chromatography indicated that this was due to a further
increase in the very low-density lipoprotein–sized remnant
lipoproteins that accumulate in Apoe-deficient mice. Whether
this finding is relevant to the clinical setting is unclear. One
study conducted a pooled analysis of lipid measurements
from 3 prospective studies comparing the antagonist abarelix
to either leuprolide monotherapy or combined therapy with
leuprolide and an androgen blocker, but found no consistent
differences in LDL concentrations between groups.32 Newer
trials comparing ADTs have been conducted, but it is still not
clear how different types of ADT treatment affect levels of
different apoB-containing lipoproteins because surprisingly
little information regarding atherosclerosis risk factors has
been reported.33 Clearly, this potentially important question
warrants further investigation.
Comparison to Previous Studies
Two previous studies have investigated the impact of GnRH
agonists and/or antagonist on very early atherosclerotic
lesion formation.16,17 In 12-week-old chow-fed Apoe-deficient
mice treated with the GnRH antagonist cetrorelix for 8 weeks,
A B
C D
Figure 5. Atherosclerosis in Apoe-deficient mice subjected to different forms of ADT. A and B, All
castration methods accelerated the development of atherosclerosis in the aortic root (A) and aortic arch (B)
to a similar degree. C and D, Necrotic core size quantified in lesions from the aortic root. No significant
differences in absolute or relative amount of necrosis were found between the groups. P-values were
calculated using Newman–Keuls post-test after significant ANOVA (A through D). *P<0.05, **P<0.01.
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von Dehn et al found initial foam cell accumulation to be
reduced compared to controls.16 Hopmans et al17 reported
significantly increased atherosclerosis in chow-fed
Ldlr-deficient mice following orchiectomy or treatment with
leuprolide, whereas degarelix-treated animals were in-
between and not significantly different from either leupro-
lide-treated or control mice. Notably, in both these studies,
lesion size was many-fold smaller than in our study.
Contrasting with our findings, Hopmans et al also found a
significant difference in plaque necrosis between degarelix-
and leuprolide-treated mice. Potential explanations for this
discrepancy may be the much later stage of necrotic core
formation in the present study or potential differences in the
definition of necrosis.
ADT and the Immune System
For more than a century it has been recognized that androgen
deprivation affects the immune system,34 and the GnRH
receptor has been found on immune cells from humans35,36
and rodents.13,37 Interestingly, stimulation of the GnRH recep-
tor exacerbated lupus in castrated female mice14,38 and
treatment with GnRH receptor antagonist delayed the onset
of autoimmune diabetes15 and increased the survival rate
among lupus-prone mice.14 Furthermore, treatment of preg-
nant rats with a GnRH receptor agonist caused an increase in
the cytokine interferon-c and a decrease in IL-4 production from
anti-CD3 stimulated lymphocytes,13 indicating stimulation of
pro-inflammatory Th1-type responses, which are known to be
important in atherosclerosis.39 In the present study, we tested
for such effects in murine macrophage and lymphocyte cell
culture assays, but failed to detect any changes following GnRH
receptor blockade or stimulation. The assays used were
designed to search for effects previously reported in the rat13
or in immortalized cells,12 and the results do not exclude that
other facets of murine immune cell function could bemodifiable
by GnRH receptor signaling, such as the secretion of other pro-
inflammatory or anti-inflammatory cytokines.
A B
C D
Figure 6. Atherosclerosis in orchiectomized Apoe-deficient mice receiving leuprolide or degarelix. A and
B, Aortic root atherosclerosis was significantly increased in orchiectomized mice treated with leuprolide
compared to other groups. En face analysis of the aortic arch did not demonstrate any significant effects of
leuprolide or degarelix on atherogenesis. C and D, No significant differences were found in absolute or
relative necrotic core areas between groups. P-values were calculated using Newman–Keuls post-test after
significant ANOVA (A through D). *P<0.05.
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Deprivation of sex hormones by surgical castration or
treatment with leuprolide has been found to increase thymus
size and cellularity.20,40 It involves increased proliferation of
immature thymocytes,34 but the exact mechanisms and the
potential role of local GnRH receptors have not been clarified.
Our study was consistent with previous literature in this field,
except for leuprolide, which resulted in lower thymus and
spleen weights compared to mice subjected to bilateral
orchiectomy or degarelix. The reasons for this warrant further
investigation, and it is apparently in conflict with a previous
study using a lower dose of leuprolide in nonorchiectomized
male mice.41
Limitations
Our experimental approach is far from exhaustive in address-
ing the many ways in which ADT could affect the occurrence
of clinical atherosclerotic CVD. Myocardial infarction and
stroke is the result of a decade-long process of plaque
development suddenly complicated by thrombosis, most often
precipitated by rupture of the fibrous cap and resultant
exposure of the necrotic core.42 The observed increase in risk
following ADT therapy can therefore potentially be attributed
to effects on any of several processes, including mechanisms
in the atherosclerotic plaque that increase propensity to
rupture, processes that augment plaque thrombogenicity, or
factors outside the atherosclerotic lesion, such as systemic
thrombotic tendency and myocardial susceptibility to ische-
mia that may increase the likelihood that rupture leads to a
clinical event.43
Conclusions
Leuprolide augmented hypercholesterolemia, but no signifi-
cant differences in the development of atherosclerosis were
detected among groups of intact Apoe-deficient mice treated
with different types of ADT. A pro-atherogenic, possibly
cholesterol-mediated, effect of leuprolide was seen in
orchiectomized mice that might be relevant for understanding
A B
C D E
Figure 7. ADT and immune cell activation. A, Detection of GnRH receptor mRNA in cultured BMMs and splenocytes. Spl-S and Spl-C indicate
splenocytes cultured with or without 3 lg/mL anti-CD3 for 48 h, respectively. BMM-S and BMM-C indicate bone marrow–derived macrophages
cultured with or without 100 ng/mL LPS for 24 h, respectively. Pit, pituitary gland. Pit-RT, Control reaction with omission of reverse
transcriptase. B through D, IL-6, MCP-1 and TNF-a secretion from LPS-stimulated macrophages in the presence of leuprolide or degarelix at a
concentration of 106 mol/L. No significant differences were observed between the groups for any concentration of LPS. Number of biological
replicates for measurements of IL-6 at LPS concentrations of 1, 10, and 100 ng/mL: Control (n=16, 26, 27); leuprolide (n=18, 25, 28); degarelix
(n=16, 25, 26). For MCP-1 measurements: Control (n=14, 20, 24); leuprolide (n=14, 23, 24); degarelix (n=14, 21, 24). For TNF-a: Control (n=16,
26, 27); leuprolide, (n=18, 26, 28); degarelix (n=16, 25, 27). E, Relative number of anti-CD3 stimulated splenocytes after 48 h in the presence of
degarelix or leuprolide at a concentration of 106 mol/L (n=16 in each group). ADT, androgen deprivation therapy; GnRH, gonadotropin-
releasing hormone; LPS, lipopolysaccharide; MCP-1, monocyte chemotactic protein-1; TNF, tumor necrosis factor.
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the potential cardiovascular risk associated with GnRH
agonist-based ADT.
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